FDA Approves First-in-Class Pill for Tough to Treat High Blood Pressure

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Hypertension, or high blood pressure, is a condition where blood pushes too hard against artery walls, increasing health risks.

First new drug class in decades.Before Baxfendy, doctors had no new type of blood pressure medication for resistant hypertension in over 30 years. This pill offers a fresh option for patients who have not responded to existing drugs.
Targets treatment resistant patients.Millions of people take multiple blood pressure pills but still have dangerously high readings. Baxfendy works differently by blocking aldosterone production, giving these patients a new chance to lower their numbers.
Add on therapy for better control.The drug is designed to be taken alongside other antihypertensives, not replace them. This means patients can keep their current regimen and simply add Baxfendy to improve results without starting over.
Oral pill for daily convenience.Unlike some newer treatments that require injections or infusions, Baxfendy is a simple once daily pill. This makes it easier for patients to stick with their treatment and manage their condition at home.

The U.S. Food and Drug Administration has approved a new type of blood pressure pill designed for the millions of patients whose hypertension remains dangerously high despite standard treatments. The drug, developed by AstraZeneca, marks the first approval in a new class of medications for uncontrolled hypertension in decades.

The medication, which will be sold under the brand name Baxfendy, is the first aldosterone synthase inhibitor cleared for high blood pressure. It is intended for use alongside other antihypertensives in patients with treatment-resistant or uncontrolled hypertension. In a pivotal Phase 3 study published in the New England Journal of Medicine, a 2 mg daily dose of Baxfendy lowered systolic blood pressure by 9.8 mmHg more than placebo after 15 weeks. Even a lower 1 mg dose produced a statistically significant 8.7 mmHg improvement.

Baxfendy works by blocking the aldosterone synthase enzyme, which controls a hormone that prompts the body to retain sodium. When left unchecked, this process can drive blood pressure higher. The drug is taken once daily as a pill. AstraZeneca acquired the therapy in 2023 through its $1.3 billion purchase of CinCor Pharma. The company estimates that around 23 million people in the United States could be eligible for treatment, part of a global population of roughly 1.4 billion living with hypertension.

Expanding the Treatment Landscape

AstraZeneca is also studying Baxfendy for other cardiovascular conditions, including primary aldosteronism, chronic kidney disease, and heart failure prevention, all of which are in late-stage trials. The company has identified the drug as a key growth driver, projecting peak sales above $5 billion. Analysts at Leerink Partners have suggested the revenue potential could reach $10 billion if the drug succeeds in additional indications.

A competitor is not far behind. Mineralys Therapeutics has submitted its own aldosterone synthase inhibitor, lorundrostat, for FDA review, with a decision expected in December. The arrival of this new drug class offers fresh hope for patients who have not responded well to existing therapies.

With the FDA’s green light, Baxfendy is expected to reach U.S. pharmacies soon. For the millions of people whose blood pressure remains stubbornly high, this new option could mark a meaningful shift in their daily management and long term health outlook.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.